^
    Back
    Association details:
    Biomarker:NOTCH3 overexpression
    Cancer:Pancreatic Cancer
    Drug:tarextumab (OMP-59R5) (Notch-2 receptor inhibitor, Notch-3 receptor inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer

    Excerpt:
    ...Phase 2: Overall Survival (ITT Population)`To determine the clinical benefit, as measured by OS of the addition of OMP-59R5 to Nab-P+Gem across the 4 subject subsets: subjects with Notch3 ≥ 25th percentile, subjects with Notch3 ≥ 50th percentile, subjects with Notch3 ≥ 75th percentile and all subjects receiving first-line therapy for stage IV pancreatic cancer with Notch3 high expression level.`...
    Trial ID:
    NCT01647828
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Clin Cancer Res
    Title:

    Targeting Notch signaling with a Notch2/Notch3 antagonist (tarextumab) inhibits tumor growth and decreases tumor-initiating cell frequency

    Excerpt:
    We utilized patient-derived xenograft tumors to evaluate antitumor effect of OMP-59R5...Notably, the sensitivity of anti-Notch2/3 in combination with gemcitabine in pancreatic tumors was associated with higher levels of Notch3 gene expression.
    Secondary therapy:
    gemcitabine
    DOI:
    10.1158/1078-0432.CCR-14-2808